REFERENCES—(WVSMA Special Edition-Prescription Drug Abuse-Article by P.B. Hall MD)
1. Manchin III J. The governor’s comprehensive strategic plan to address substance abuse in West Virginia.
The West Virginia Prevention Resource Center. 2009 (November) Available at:
http://www.prevnet.org/wvpartnership/docs/Plan.pdf. (Accessed: March 20, 2010.)
2. Leshner, A.I. (1997). Addiction is a Brain Disease, and it Matters. Science, 1997;278 (5335): 4547.
3. I-han C, Narasimhan K (eds). Neurobiology of Addiction. Nature Neuroscience. 2005;8(11):all.
4. White, W.L. In search of the neurobiology of addiction recovery: a brief commentary on
science and stigma. 2007(August):all. Available at:
http://wsam.org/files/White_neurobiology_2007.pdf. (Accessed April 4, 2010).
5. McLellan, AT, Skipper, GS, Campbell, M, DuPont, RL, Five Year Outcomes in a Cohort
Studies of Physicians Treated for Substance Use Disorders in the United States. BMJ.
2008;337(November):a2038, doi: 10.1136/bmj.a2038.
6. American Society of Addiction Medicine. (2003). In Principles of Addiction Medicine, 3rd Edition.
Chevy Chase MD: ASAM. Section 1, Chapter 2, The Epidemiology of Addictive Disorders,
page 20.
7. National Institute on Drug Abuse. NIDA InfoFacts: Treatment Approaches for Drug Addiction.
Washington D.C.: U.S. Department of Health and Human Services. 2009 (September): all
8. Substance Abuse and Mental Health Services. Report on illicit drug use among older adults
2006-2008. ASMA News. 2010;25(1):14.
9. National Institute on Drug Abuse. NIDA InfoFacst: Treatment Approaches for Drug Addiction.
Washington D.C.: U.S. Department of Health and Human Services. 2008 (June): all
10. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, et al. Patterns of abuse among
unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.
11. Hall, P.B. M.D. “A Lessor Evil for Drug Addicts”, Editorial Response to the Toronto Sun.
May 2009.
12. Gurley, R.J., Aranow, R., Katz, M. “Medical Marijuana: A Comprehensive Review”.
Journal of Psychoactive Drugs. 1998;30(2), 137-148.
1|Page
13. National Institute Drug Abuse . Principles of drug addiction: a research based guide. 2nd ed.
Washington, DC: US Department of Health and Human Services. NIH Publication No. 084180. 2008 (revised 2009):all.
14. Rothman, B, O’Gorman P. Working with traumatized and addicted adolescents”. Counselor,
2008;9(6):24-29.
15. American Psychiatric Association. Substance-related disorders. In: American Psychiatric
Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed (text revision).
Washington, D.C.: American Psychiatric Association. 1994;191-295.
16. Buchsbaum DG, Buchanan RG, Center RM, Schnoll SH, Lawton MJ. Screening for alcohol
abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991;115:774-7.
17. Saudners JB, Assland OG, Babor TF, Fuente Jr, Grant M. Development of the Alcohol Use
Disorders Identification Test (AUDIT): WHO collaborative project on early detection of
persons with harmful alcohol consumption-II. Addiction. 1993;88:791-804.
18. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic
instrument. Am J Psychiatry. 1971;127:1653-8.
19. McLellan, A. Thomas PhD, et al. “Drug Dependence, a Chronic Medical Illness – Implications
for Treatment, Insurance, and Outcomes Evaluation”, JAMA. 2000;(284 (13):1689-1695.
20. Buchsbaum DG, Buchanan RG, Lawton MJ, Elswick RK Jr., Schnoll SH. A program of
screening and prompting improves short-term physician counseling of dependent and
nondependent harmful drinkers. Arch Intern Med. 1993; 153:1573-7.
21.Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a singlequestion alcohol screening test. Journal of Internal Medicine, 2009; 24(7):783-788
22.Metzger DS, Woody GE, McLellan AT, et al. HIV seroconversion among intravenous drug
users in and out of treatment. AIDS. 1993;6:1049-1056.
23.Svikis DS, Golden AS, Huggins GR, et al. Cost effectiveness of treatment for drug
abusing pregnant women. Drug Alcohol Depend. 1997;45:105-113.
24. American Society of Addiction Medicine. (2003). In Principles of Addiction Medicine, 3rd Edition.
Chevy Chase MD: ASAM. Section 4, Chapter 6, Relapse Prevention: Clinical Models and
Intervention Strategies, page 468.
25. O’Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet.
1996;347:237-240.
26. Tsuang MT, Lyons MJ, Eisen S, et al. Genetic influences on DSM-III-R drug abuse and
dependence: a study of 3,372 twin pairs. Am J Med Genet. 1996;67:473-477.
2|Page
27. VandenBree M, Johnson E, Neale M, Pickens R. Genetic and environmental influences on
drug use and abuse/dependence in male and female twins. Drug Alcohol Depend. 1998;52:231241.
28. Williams RR, Hunt SC, Hasstedt SJ, et al. Are there interactions and relations between
genetic and environmental factors predisposing to high blood pressure? Hypertension.
1991;18(suppl)129-137.
29. Kaprio J, Tuomilehto J, Koskenvuo M, et al. Concordance for type 1 (insulin-dependent)
and type 2 (non-insulin dependent) diabetes mellitus in a population-based cohort of twins
in Finland. Diabetologia. 1992;35:1060-1067.
30. Nieminen MM, Kaprio J, Koskenvuo M. A population-based study of bronchial asthma
in adult twin pairs. Chest. 1991;100:70-75.
31. Samet JM. Occupation pulmonary disorders. In: Goldman L, Ausiello D. Cecil Textbook of
Medicine 22ed. Philadelphia, PA: Saunders. 2004:532-538.
32. Svhuckit MA, Smith TL. An 8-year follow-up of 450 sons of alcoholics and controls.
Gen Psychiatry. 1996;53:202-210.
Arch
33. Thomasson HR, Edenberg HJ, Crabb DW, et al. Alcohol and aldehyde dehydrogenase
genotypes and alcoholism in Chinese men. Am J Hum Genet. 1991;48:667-681.
34. National Institute on Drug Abuse. Drugs, Brain and Behavior: The Science of Addiction. NIH Pub.
No. 07-5605. Washington, D.C.: National Institute on Drug Abuse 2007: all.
35. Ross S. Peselow E. The Neurobiology of Addictive Disorders. Clinical Neuropharmacology
2009;32(5):269-276.
36. Koob GF. Drug addiction: The Yin and Yang of Hedonic Homeostasis. Neuron. 1996; 16, 893896.
37. Kauer JA, Malenka RC. Synaptic Plasticity and Addiction. Nature 2007;8(11):844-853.
38. National Consensus Development Panel on Effective Medical Treatment of Opiate
Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936-1943.
39. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: a review. Exp Clin
Psychopharmacol. 1995;3:477-489.
40. Ling W, Wesson DR. Naltrexone treatment for addicted health care professionals. J Clin.
Psychiatry. 1984;45:46-48.
3|Page
41. Cornish J, Metzger D, Woody G, et al. Naltrexone pharmacotherapy for opioid dependent
federal probations. J Subst Abuse Treat. 1998;13:477-498.
42. Sass H, Soyka M, Mann K. Ziegigasberger W. Relapse prevention by acamprosate. Arch Gen
Psychiatry. 1996;53:673-680.
43. Diehl, A, Ulmer, L, Mutschler J, Herre H, Krumm B, et al. Why is Disulfiram Superior to
Acamprosate in the Routine Clincial Setting? A retrospective long-term study in 353
alcohol-dependent patients. Alcohol and Alcoholism. 2010(March 26); doi:1093/alcalc/agq017.
44. Childress AR, McElgin W, Mozley PD, et al. Limbic activation during cue-induced
cocaine craving. Am J Psychiatry. 1999;156:1, 11-18.
45. American Society of Addiction Medicine. (2003). In Principles of Addiction Medicine, 3rd Edition.
Chevy Chase MD: ASAM. Section 4, Chapter 11, Special Issues in Treatment Drug Courts,
page 543-545.
46. Cartwright WS. Cost-benefit analysis of drug treatment services: review of the literature.
The Journal of Mental Health Policy and Economics. 2000;2(July):11-26.
47. Ettner SL et al. Benefit-cost in the California Treatment Outcome Project: Does substance
abuse treatment pay for itself? Health Services Research 41(1):193-213, 2006.
48. Sullivan E, Fleming M. (consensus panel co-chairs). TIP 24: A guide to substance abuse
services for primary care clinicians: treatment improvement protocol (TIP). In: Substance
Abuse and Mental Health Service Administration's Center for Substance Abuse Treatment.
SAMHSA/CSAT Treatment Improvement Protocols. DHHS Publication No. (SMA) 97-3139.
1997. Available at:
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hssamhsatip&part=A45504.
(Accessed: April 5, 2010.)
49. American Society of Addiction Medicine. (2003). In Principles of Addiction Medicine, 3rd Edition.
Chevy Chase MD: ASAM. Section 4, Chapter 5, The ASAM Placement Criteria and
Matching Patients to Treatment, page 453-459.
50. Miller T, Hendrie D. Executive summary. In: Miller T, Hendrie D. Substance abuse
prevention dollars and cents: a cost-benefit analysis. DHHS Pub. No. (SMA) 07-4298.
Rockville, MD: Center for Substance Abuse Prevention, Substance Abuse and Mental Health
Services Administration. 2009:4-5.
51. Federation of State Physician Health Programs, Inc. Public Policy Statement: Physician Illness vs.
Impairment. 2008. Available at: http://www.fsphp.org/Illness_vs_Impairment.pdf.
4|Page